• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Loneliness Is a Public Health Emergency. Here ’s What Helps, According to Experts
When the pandemic first began, many experts feared that even people who managed to avoid the virus would suffer from unprecedented levels of loneliness. What would happen when millions of people were told to stay at home and distance themselves from friends and loved ones? Two years of research later, experts have found that the pandemic did make Americans slightly more lonely—but loneliness levels were already dire enough to pose a threat to mental and physical health. Here’s what you need to know about loneliness and how to address it in your own life. Who got lonelier during the pandemic? [time-brightcove n...
Source: TIME: Health - June 1, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Loneliness Is a Public Health Emergency. Here ’ s What Helps, According to Experts
When the pandemic first began, many experts feared that even people who managed to avoid the virus would suffer from unprecedented levels of loneliness. What would happen when millions of people were told to stay at home and distance themselves from friends and loved ones? Two years of research later, experts have found that the pandemic did make Americans slightly more lonely—but loneliness levels were already dire enough to pose a threat to mental and physical health. Here’s what you need to know about loneliness and how to address it in your own life. Who got lonelier during the pandemic? [time-brightcove n...
Source: TIME: Health - June 1, 2022 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Post-hoc Study of D-Amino Acid Oxidase in Blood as an Indicator of Post-stroke Dementia
In conclusion, our data support that plasma DAO levels were increased in PSD patients and correlated with brain WMH, independent of age, gender, hypertension, and renal function. Plasma DAO levels may therefore aid in PSD diagnosis. Introduction Stroke is a risk factor for both vascular dementia and Alzheimer's disease (1, 2). Functional recovery develops over the course of 26 weeks after a stroke (3), but the survivors are often left with disabilities. In addition to the sequelae of acute neuronal damage, the 1-year post-stroke dementia (PSD) rates after first-ever and recurrent stroke are ~10 and 30...
Source: Frontiers in Neurology - April 25, 2019 Category: Neurology Source Type: research

Glutamate Transport and Preterm Brain Injury
Silvia Pregnolato1*, Elavazhagan Chakkarapani1, Anthony R. Isles2 and Karen Luyt1 1Department of Neonatal Neurology, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom 2Behavioural Genetics Group, MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, United Kingdom Preterm birth complications are the leading cause of child death worldwide and a top global health priority. Among the survivors, the risk of life-long disabilities is high, including cerebral palsy and impairment of movement, cognition, and beh...
Source: Frontiers in Physiology - April 23, 2019 Category: Physiology Source Type: research

CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - November 1, 2017 Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research